GSGilad Segev

Gilad Segev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gilad Segev has a total of 143 co-authors. Here are the top co-authors by number of shared publications:

  • Itamar Aroch

    The Koret School of Veterinary Medicine, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem , Jerusalem

    13 shared publications
  • Hilla Chen

    Koret School of Veterinary Medicine, The Hebrew University of Jerusalem Department of Small Animal Internal Medicine Rehovot

    12 shared publications
  • Efrat Kelmer

    Department of Small Animal Emergency and Critical Care The Hebrew University of Jerusalem Rehovot Israel

    7 shared publications
  • Jodi L. Westropp

    University of California Davis Department of Veterinary Medicine and Epidemiology Davis, California

    6 shared publications
  • Michal Mazaki-Tovi

    Koret School of Veterinary Medicine, The Hebrew University of Jerusalem , Rehovot 7610001

    6 shared publications
  • Sigal Klainbart

    Department of Small Animal Emergency and Critical Care The Veterinary Teaching Hospital, Koret School of Veterinary Medicine, The Robert H Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem Rehovot Israel

    6 shared publications

Latest Publications

  • Open Access

    2026 iCatCare consensus guidelines on the diagnosis and management of chronic kidney disease in cats

    by Samantha Taylor, Natalie Finch, Sarah Caney, Jonathan Elliott, Rebecca Geddes, Femke Mortier, Valerie Parker, Jessica Quimby, Gilad Segev, Joanna White

    Practical relevance: Chronic kidney disease (CKD) is common in senior cats. Early diagnosis can facilitate interventions to slow progression and minimise clinical signs. Management according to the International Renal Interest Society (IRIS) staging system for CKD can lead to prolonged survival and an excellent quality of life for affected cats. Aim: The ‘2026 iCatCare consensus guidelines on the diagnosis and management of chronic kidney disease in cats’ provide information on the pathogenesis of CKD, guidance on making a diagnosis and staging of disease, and practical content on medical and nutritional treatment. They also discuss optimising the home and veterinary clinic environment to positively influence mental wellbeing and, in turn, physical health, as well as working with the whole veterinary team and caregivers to slow disease progression and maximise quality of life. Clinical challenges: Affected cats may show minimal or no clinical signs in the early stages of CKD, which can result in a delay in diagnosis. The condition is generally progressive and management requires consideration of multiple factors in order to address clinical signs. Complications such as hypercalcaemia, hypertension, proteinuria and anaemia may develop, requiring treatment. Moreover, as advancing age is a risk factor for CKD, cats may have important comorbidities that need to be balanced, with impacts on the kidney. Caring for a cat with CKD can result in caregiver burden. Hence, supporting caregivers, contextualising monitoring to the individual cat, and involving both the veterinary and nursing teams is important. Evidence base: These Guidelines have been created by a panel of experts brought together by International Cat Care (iCatCare) Veterinary Society. Information is based on the available literature, expert opinion and the panel members’ experience. Specific abbreviations: ACE = angiotensin-converting enzyme; ACKD = acute-on-chronic kidney disease; AKI = acute kidney injury; ARB = angiotensin receptor blocker; CKD = chronic kidney disease; CKD-MBD = CKD–mineral and bone disorder; FGF23 = fibroblast growth factor 23; GFR = glomerular filtration rate; iCa = ionised calcium; ICGN = immune-complex glomerulonephritis; IRIS = International Renal Interest Society; PTH = parathyroid hormone; SDMA = symmetric dimethylarginine


  • Open Access

    International renal interest society best practice consensus guidelines on the use of continuous renal replacement therapy in dogs and cats

    by Hilla Chen, Larry D. Cowgill, Thierry Francey, Rosanne E. Jepson, Catherine Langston, Ariane Schweighauser, Gilad Segev


  • Open Access

    Effects of Paricalcitol on Renal Secondary Hyperparathyroidism and Proteinuria in Dogs With Chronic Kidney Disease

    by Hilla Chen, Gilad Segev, Michal Mazaki-Tovi

    Background: Renal secondary hyperparathyroidism (RHPT) is an inevitable consequence of chronic kidney disease (CKD). Paricalcitol might safely attenuate RHPT and proteinuria. Hypothesis/Objective: Paricalcitol decreases parathyroid hormone (PTH) and proteinuria in dogs with CKD. Animals: Thirteen dogs with naturally acquired CKD. Methods: Placebo-controlled clinical trial. Dogs were randomly allocated to receive a placebo or paricalcitol (14 ng/kg/day) in a crossover design of 2, 12-week arms. Dogs were evaluated every 3 weeks. Associations between treatment, visit, and the outcome variables were assessed using generalized estimating equations. Results: PTH decreased by 22% (95% CI, 7%–35%, p = 0.006) in the paricalcitol-treated dogs and increased by 18% (95% CI, 2%–37%, p = 0.022) in the placebo-treated dogs with each visit. FGF-23 at 12 weeks increased compared with baseline in the paricalcitol-treated (mean 6941 pg/mL, 95% CI, 1781–20 057 vs. 489 pg/mL, 95% CI, 188–1272, p < 0.001, respectively), but not in the placebo-treated dogs (696 pg/mL, 95% CI, 316–1531 vs. 955 pg/mL, 95% CI, 308–2963, p = 0.529). Urine protein-to-creatinine ratio at 12 weeks increased compared with baseline in the placebo-treated (0.8, 95% CI, 0.3–1.3 vs. 0.5, 95% CI, 0.2–0.9, p = 0.04, respectively), but not in the paricalcitol-treated dogs (0.6, 95% CI, 0.3–0.9 vs. 1.0, 95% CI, 0.1–1.8, p = 0.35). Ionized calcium was unchanged between baseline and 12 weeks in the paricalcitol- and placebo-treated groups (1.3 mmol/L, 95% CI, 1.29–1.35 and 1.34, 95% CI, 1.27–1.40 vs. 1.30, 95% CI, 1.25–1.35, p = 0.12 and 1.28, 95% CI, 1.24–1.32, p = 0.034, respectively). However, 7/13 dogs developed mild hypercalcemia. Adverse effects were not reported by the owners. Conclusion and Clinical Importance: Paricalcitol attenuated RHPT and stabilized renal proteinuria in dogs with CKD.


  • Open Access

    Clinical findings, prognostic factors, and outcome of protein-losing nephropathy in cats: A retrospective study

    by Noam Sugar, Hilla Chen, Gilad Segev

    Background: Primary glomerular disease resulting in protein-losing nephropathy (PLN) is an uncommon cause of chronic kidney disease in cats, yet is important to recognize because it warrants specific treatment that impacts outcome. Hypothesis/Objective: Characterize clinicopathologic findings, prognostic indicators, and short- (≤30 days) and long-term survival of cats with PLN. Animals: Thirty-seven cats with naturally occurring PLN. Methods: Medical records of cats with PLN admitted to a veterinary teaching hospital were retrospectively reviewed. Results: Median age was 3 years (range, 1.5-11.5 years) and 17/37 (46%) were males. Short-term survival was 57%. The estimated median survival time of all cats was 424 days (95% confidence interval [CI], 0-1098 days). Common clinical signs included lethargy (57%), edema (46%) and weight loss (35%). Edema was more common in short-term survivors compared with nonsurvivors (odds ratio [OR], 0.21; 95% CI, 0.05-0.86-20.4; P = .04). Serum creatinine concentration at presentation was negatively associated with long-term survival (OR, 1.3; 95% CI, 1.03-1.52; P = .01). Administration of immunosuppressive and antiproteinuric medications was more common among short-term survivors compared with nonsurvivors (18/20 [90%] vs 9/16 [56%]; OR, 7.0; 95% CI, 1.2-40.8; P = .05 and 17/20 [85%] vs 7/16 [44%]; OR, 7.3; 95% CI, 1.5-35.2; P = .01, respectively). Partial or complete remission was documented in 11/31 (36%) cats and was associated with both short (OR, 3.3; 95% CI, 1.7-6.5; P < .001) and long-term survival (P = .003). Conclusion and Clinical Importance: Cats with PLN have a guarded prognosis, but achieving remission improves outcome. Cats presented with edema rather than azotemia are more likely to respond to treatment.


  • Open Access

    Evaluation of oxidative stress in dogs and cats with chronic kidney disease

    by Hilla Chen, Gilad Segev

    Background: Oxidative stress is a potential contributor to chronic kidney disease (CKD) progression but has not been evaluated in dogs and cats with CKD. Hypothesis: Oxidative stress is higher in animals with CKD compared with healthy controls and decreases with the advancing CKD stage. The aim of this study was to determine the presence and intensity of oxidative stress in dogs and cats at different CKD stages. Animals: Sixty dogs and 30 cats with naturally acquired CKD; 10 dogs and 14 cats, healthy controls. Methods: Analytical cross-sectional study. Oxidative stress was evaluated by measuring the urinary concentration of F2-isoprostane (uF2-IsoPs) normalized to urinary creatinine. Results: Urinary F2-isoprostanes normalized to urinary creatinine of healthy dogs and of dogs with CKD Stages 1 to 4 was 3.3 ng/mg, 4.7 ng/mg (range, 1.0-73.4), 2.4 ng/mg (range, 0.4-7.8), 0.52 ng/mg (range, 0.01-2.9), and 0.37 ng/mg (range, 0.01-0.6), respectively. Urinary F2-isoprostanes differed among CKD stages (P < .001), but not compared with controls. uF2-IsoPs of healthy cats and cats with CKD Stages 1 to 4 was 0.68 ng/mg (range, 0.2-1.4), 0.97 ng/mg (range, 0.4-1.8), 0.6 ng/mg (range, 0.002-2.0), 0.94 ng/mg (range, 0.3-2.3), and 0.2 ng/mg (range, 0.01-0.4). Urinary F2-isoprostanes differed among stages (P = .05) but not compared with healthy controls. Conclusion and Clinical Importance: Oxidative stress might be present in dogs and cats with CKD. Its magnitude declines as the disease progresses, therefore, it should be considered a potential therapeutic target mostly at the early stages of the disease.


  • Open Access

    Evaluation of the efficacy of a live Escherichia coli biotherapeutic product (asymptomatic bacteriuria E. coli 212)

    by Gilad Segev, Hilla Chen, Jonathan D. Dear, Beatriz Martínez López, Jully Pires, David J. Klumpp, Anthony J. Schaeffer, Jodi L. Westropp

    Background: Recurrent bacterial cystitis, often referred to as recurrent urinary tract infection (UTI), can be difficult to manage and alternative treatments are needed. Hypothesis/Objective: Intravesicular administration of asymptomatic bacteriuria (ASB) E. coli 212 will not be inferior to antimicrobial treatment for the management of recurrent UTI in dogs. Animals: Thirty-four dogs with >1 UTI in the 12 months before presentation. Methods: All dogs were deemed normal otherwise based on absence of abnormalities on physical examination, CBC, serum biochemical panel, and abdominal ultrasonography. Dogs were randomized to 1 of 2 treatment groups: Group 1 antimicrobials for 7 days or group 2 intravesicular administration of ASB E. coli 212. Owners were provided a voiding questionnaire regarding their dogs' clinical signs, which was completed daily for 14 days to assess clinical cure. Dogs were examined on days 7 and 14 to assess clinical cure, and urine specimens were submitted for urinalysis and bacterial culture. Results: Clinical cure rates for ASB E. coli 212–treated dogs were not inferior to 7 days of antimicrobial treatment with a 12% margin of difference to determine non-inferiority. No significant difference was found between the treatment groups on days 7 and 14 in the proportion of dogs achieving ≥50% or ≥75% reduction in their clinical score compared with baseline. Conclusions and Clinical Importance: These data suggest that intravesicular administration of ASB E. coli 212 is not inferior to antimicrobials for the treatment of recurrent UTI in dogs. This biotherapeutic agent could help alleviate the need for antimicrobials for some dogs with recurrent UTI, improving antimicrobial stewardship.

  • Retrospective evaluation of traumatic pneumomediastinum in dogs and cats (2005–2022): 52 cases

    by Sigal Klainbart, Anna Shipov, Daliya Tygiel, Gilad Segev, Efrat Kelmer

    Objective: To describe the incidence, etiology, clinical signs, diagnostics, treatments, and outcome of noniatrogenic traumatic pneumomediastinum (TPM) in dogs and cats.Design: Retrospective study of cases (2005–2022).Setting: University veterinary teaching hospital.Animals: Fifty‐two patients (29 dogs, 23 cats).Measurements and Main Results: Data collected from the medical records included signalment, physical examination findings, animal trauma triage (ATT) score, clinicopathological data, imaging data, surgical intervention, length of hospitalization, supportive care, complications, and outcome. Most dogs presented with tachycardia and tachypnea, while cats presented with hypothermia and tachypnea. Subcutaneous emphysema, pneumothorax, and dyspnea were the most common clinical signs for both species. The median calculated ATT score was 3.5 in dogs and 4 in cats. The most common radiographic abnormalities other than pneumomediastinum were pneumothorax and lung contusions. The overall mortality rate was 18%, with a significantly higher survival rate in dogs (26/28 dogs [93%], 15/22 cats (68%); P = 0.03). Outcome was unknown in 1 dog and 1 cat. The only significant difference in treatment between survivors and nonsurvivors was the requirement in dogs for positive pressure ventilation. The median hospitalization period was 2 days for both species, with a shorter hospitalization in the nonsurvivors (0.6 vs 2 days, respectively; P = 0.006).Conclusions: TPM is an infrequent pathology in veterinary medicine and may be seen without an externally obvious injury. The most common causes for TPM in dogs were vehicular trauma and bite wounds, while high‐rise syndrome was the most common cause in cats. Most of the cases have concurrent pneumothorax and require thoracocentesis; however, direct intervention to treat TPM is not usually required. The vast majority of cases did not undergo surgery to treat TPM. The prognosis for dogs with TPM was good but was guarded for cats.


  • Open Access

    Thromboelastometry for assessment of hemostasis and disease severity in 42 dogs with naturally-occurring heatstroke

    by Michal Yanai, Sigal Klainbart, Gal Dafna, Gilad Segev, Itamar Aroch, Efrat Kelmer

    Background: Thromboelastometry (TEM) provides a comprehensive overview of the entire coagulation process and has not been evaluated in heatstroke-induced coagulopathies in dogs. Objectives: To determine the diagnostic and prognostic utility of TEM in dogs with heatstroke. Animals: Forty-two client-owned dogs with heatstroke. Methods: Prospective observational study. Blood samples for intrinsic and extrinsic TEM (INTEM and EXTEM, respectively) were collected at presentation and every 12 to 24 hours for 48 hours. Coagulation phenotype (hypo-, normo-, or hypercoagulable) was defined based on TEM area under the 1st derivative curve (AUC). Results: Case fatality rate was 31%. Median TEM variables associated with death (P < .05 for all) included longer INTEM clotting time, lower AUC at presentation and at 12 to 24 hours postpresentation (PP), lower INTEM alpha angle, maximum clot firmness, and maximum lysis (ML) at 12 to 24 hours PP, and lower EXTEM ML at 12 to 24 hours PP. Most dogs were normo-coagulable on presentation (66% and 63% on EXTEM and INTEM, respectively), but hypo-coagulable 12 to 24 PP (63% for both EXTEM and INTEM). A hypo-coagulable INTEM phenotype was more frequent at presentation and 12 to 24 PP among nonsurvivors compared to survivors (55% vs 15% and 100% vs 50%, P = .045 and .026, respectively). AKI was more frequent (P = .015) in dogs with hypo-coagulable INTEM tracings at 12 to 24 hours. Disseminated intravascular coagulation was more frequent (P < .05) in dogs with a hypo-coagulable INTEM phenotype and in nonsurvivors at all timepoints. Conclusions and Clinical Relevance: Hypocoagulability, based on INTEM AUC, is predictive of worse prognosis and occurrence of secondary complications.


  • Open Access

    International renal interest society best practice consensus guidelines for intermittent hemodialysis in dogs and cats

    by Gilad Segev, Jonathan D. Foster, Thierry Francey, Catherine Langston, Ariane Schweighauser, Larry D. Cowgill


  • Top Cited Papers
    Open Access

    International Renal Interest Society best practice consensus guidelines for the diagnosis and management of acute kidney injury in cats and dogs

    by Gilad Segev, Stefano Cortellini, Jonathan D. Foster, Thierry Francey, Catherine Langston, Leonel Londoño, Ariane Schweighauser, Rosanne E. Jepson